- News & Media
Unique Antibody Generation Approach for Cancer Immunotherapy:
Using 3D antigen immunization technology, we aim to increase the therapeutic window and the blocking functionality of antibodies for cancer treatment. This technology enables the development of new therapeutic antibodies for immuno-oncology that address key limitations of existing antibody drugs and methodologies. We expect to bring functional blocking antibodies with exclusive binding qualities and with the ability to address 3-dimensional structure of discontinuous epitopes, qualities that are proving to be vital for cancer immune-therapy.
Several antibodies for cancer immunotherapy have recently resulted in meaningful improvements and clinical efficacy in treating cancer. The mechanism of action of such antibodies is based on blocking a receptor from interacting with certain ligands. However, these therapeutic antibodies have only partial clinical response rate. In addition, a certain portion of patients stop the treatment due to toxicity, as such antibodies trigger immune-related adverse events. These toxicities limit the therapeutic benefit of the treatment.
We use a unique 3D antigen design methodology to develop new antibody therapies that aim to have exclusive binding qualities over targeted domains, block the receptor/ligand interaction with high affinity, and aim to offer a lower therapeutic dosage to limit immune-related adverse events.